CSL Seqirus expands U.S. influenza vaccine availability after 2026/27 campaign completion
Reuters reports CSL Seqirus expanded U.S. availability of its influenza vaccine following successful completion of the 2026/27 manufacturing campaign.
Reuters reports CSL Seqirus expanded U.S. availability of its influenza vaccine following successful completion of the 2026/27 manufacturing campaign.